All articles tagged with #astellas
Originally Published 2 months ago — by Investor's Business Daily
Pharma companies Pfizer, Merck, and Astellas reported promising results from a study showing that their drug combination of Padcev and Keytruda significantly extends survival and reduces recurrence in muscle-invasive bladder cancer patients, offering new hope for treatment options.
Originally Published 2 years ago — by STAT
Astellas has withdrawn its lawsuit against the Biden administration after its drug Xtandi was not selected for Medicare's drug price negotiation program. The company maintains that the program is "bad policy and unconstitutional."
Originally Published 2 years ago — by Endpoints News
Astellas is partnering with startup Kate Therapeutics to revisit X-linked myotubular myopathy, a fatal neuromuscular condition for which there are currently no treatments. The move comes four years after Audentes Therapeutics presented powerful data on a young boy with the condition at a cell and gene therapy conference.
Originally Published 2 years ago — by Endpoints News
Johnson & Johnson has paid $245m upfront for global development and commercialisation rights to two early-stage, autologous CAR-T therapy programmes from CBMG, which has a track record of allying itself with the biggest names in the development world. Astellas Pharma is to buy Iveric Bio for $5.9bn in cash, while Pfizer is focusing on M&A and oncology as Covid sales decline. The US government's court battle has begun over Gilead HIV drug patents, while Boehringer Ingelheim is to construct a $300m+ facility at its HQ. Sanofi is using its sponsorship of the Paris Olympics to encourage employees to find their potential, while Novo Nordisk is teaming up with a professional soccer player living with type 1 diabetes to highlight the possibilities of a life with the chronic disease.
Originally Published 2 years ago — by Endpoints News
Astellas Pharma has announced its acquisition of Iveric Bio for $5.9 billion in cash, as the Tokyo-based drugmaker prepares for a potential showdown with Apellis Pharmaceuticals in geographic atrophy. The deal comes amid a string of buyouts by Big Pharmas in recent weeks, as they hunt for late-stage drug candidates to boost their aging pipelines.
Originally Published 2 years ago — by Endpoints News
Pfizer and Astellas have reported that their drug Xtandi, in combination with leuprolide, reduces the risk of metastasis and death in prostate cancer by 58%. The Phase III EMBARK trial tested Xtandi plus leuprolide and Xtandi as a monotherapy against placebo plus leuprolide in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence. The companies believe that the data shows the potential for Xtandi to be added to the standard of care if a label expansion is approved.
Originally Published 2 years ago — by Financial Times
Japanese pharmaceutical company Astellas is set to acquire US biotech firm Iveric Bio for $5.9bn in a deal that will expand its ophthalmology portfolio. The acquisition will give Astellas access to Iveric Bio's gene therapy platform and pipeline of treatments for retinal diseases.
Originally Published 2 years ago — by Endpoints News
The National Institutes of Health has declined to use "march-in" rights to lower the price of Astellas and Pfizer's prostate cancer drug Xtandi despite being invented at UCLA with grants from the US Army and NIH. The institutes' analyses found Xtandi "to be widely available to the public," an indication that there was not a pressing need for the US to act. Under the Bayh-Dole Act, the government can promote the commercialization and public availability of even partially government-funded inventions, but the move has never been successful.